Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Greg Verdine
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
gptkb:cancer
oncology drug discovery therapeutics targeting transcription factors undruggable targets |
| gptkbp:foundedYear |
2015
|
| gptkbp:founder |
Greg Verdine
|
| gptkbp:fundedBy |
$178 million (Series D, 2022)
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
FogPharma
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:Polaris_Partners
gptkb:GV_(Google_Ventures) gptkb:Fidelity_Management_&_Research_Company gptkb:Venrock Crossover investors |
| gptkbp:notableEmployee |
Greg Verdine
|
| gptkbp:notableProduct |
FOG-001
|
| gptkbp:technology |
cell-penetrating miniproteins (CPMPs)
|
| gptkbp:website |
https://fogpharma.com
|
| gptkbp:bfsParent |
gptkb:Gregory_Verdine
|
| gptkbp:bfsLayer |
6
|